Page last updated: 2024-11-05

cytidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6175
CHEMBL ID95606
CHEBI ID17562
SCHEMBL ID7179
SCHEMBL ID24781031
MeSH IDM0005567

Synonyms (110)

Synonym
MLS002207040
nsc 20258
cytosine, 1-beta-d-ribofuranosyl-
1-beta-ribofuranosylcytosine
2(1h)-pyrimidinone, 4-amino-1beta-d-ribofuranosyl-
1beta-2'-ribofuranosylcytosine, d-
1beta-ribofuranosylcytosine
einecs 200-610-9
CHEMBL95606
mmv638723
cytosine-1beta-d-ribofuranoside
1-beta-d-ribofuranosylcytosine
CHEBI:17562 ,
4-amino-1-beta-d-ribofuranosyl-2(1h)-pyrimidinone
4-amino-1beta-d-ribofuranosyl-2(1h)-pyrimidinone
cytidin
zytidin
1beta-d-ribofuranosylcytosine
4-amino-1-beta-d-ribofuranosylpyrimidin-2(1h)-one
1.beta.-d-ribofuranosylcytosine
c9h13n3o5
2(1h)-pyrimidinone, 4-amino-1-.beta.-d-ribofuranosyl-
nsc-20258
cytosine riboside
.beta.-d-ribofuranoside, cytosine-1
1.beta.-ribofuranosylcytosine
4-amino-1.beta.-d-ribofuranosyl-2(1h)-pyrimidinone
cytosine, 1-.beta.-d-ribofuranosyl-
CYD ,
MLS000049947
smr000058243
D07769
posilent (tn)
cp-c
4-amino-1-.beta.-d-ribofuranosyl-2-(1h)-pyrimidinone
4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one
beta.-d-ribo-c
CTN ,
2(1h)-pyrimidinone, 4-amino-1-beta-d-ribofuranosyl-
beta-d-ribofuranoside, cytosine-1
1-beta-d-ribosyl- (6ci)
1-(beta-d-ribofuranosyl)-2-oxo-4-amino-1,2-dihydro-1,3-diazine
CYTIDINE ,
65-46-3
C00475
cytidine, bioreagent, suitable for cell culture, powder, >=99%
cytidine, 99%
DB02097
NCGC00142483-01
6D2DC474-DD76-4081-8B34-10605C218F49
BMSE000190
4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
unii-5csz8459rp
5csz8459rp ,
BMSE000969
BMSE001020
cytosine-beta-d-riboside
NCGC00093356-08
EPITOPE ID:141494
S2053
AKOS015888568
4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one
gtpl4728
cytidine [mart.]
cytidine [inci]
cytidine [mi]
cytidine [who-dd]
HY-B0158
CS-1989
1-(beta-d-ribofuranosyl)-4-aminopyrimidin-2-one
AM83932
SCHEMBL7179
J-700167
SRI-2352_17
mfcd00006545
F0348-2240
cytosine b-d-riboside
cytosine-1-b-d-ribofuranoside
cytidine, >=99.0% (hplc)
beta-d-ribofuranosyl-cytidine
cytidine; cytarabine impurity e
3h-cytidine
4-amino-1-beta-delta-ribofuranosyl-2(1h)-pyrimidinone
cytosine-1b-d-ribofuranoside
1-beta-delta-ribofuranosylcytosine
1-(b-d-ribofuranosyl)-2-oxo-4-amino-1,2-dihydro-1,3-diazine
cytosine-1b-delta-ribofuranoside
1-beta-delta-ribosyl-cytosine
1-b-d-ribofuranosylcytosine
cytosine-1beta-delta-ribofuranoside
1-beta-delta-ribofuranosyl-cytosine
4-amino-1-b-d-ribofuranosyl-2(1h)-pyrimidinone
1-beta-d-ribofuranosyl-cytosine
1-b-d-ribosyl-cytosine
1beta-delta-ribofuranosylcytosine
1-(b-delta-ribofuranosyl)-2-oxo-4-amino-1,2-dihydro-1,3-diazine
4-amino-1-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1h)-one
DTXSID60891552
Q422538
AS-12696
BRD-K71847383-001-12-5
CCG-266896
NCGC00142483-09
beta-cytidine
cytosine -d-riboside;cytosine-1--d-ribofuranoside
C-9850
EN300-184125
SCHEMBL24781031
Z1879263740
BP-58628

Research Excerpts

Overview

Cytidine is an important raw material for nucleic acid health food and genetic engineering research. It is a precursor of several antiviral drugs.

ExcerptReferenceRelevance
"Cytidine is an important raw material for nucleic acid health food and genetic engineering research. "( Overexpression of uracil permease and nucleoside transporter from Bacillus amyloliquefaciens improves cytidine production in Escherichia coli.
Fang, H; Liu, H; Ma, R; Pan, L; Wang, H; Zhang, H, 2021
)
2.28
"Cytidine is an industrially useful precursor for the production of antiviral compounds and a variety of industrial compounds. "( An enzymatic assay for high-throughput screening of cytidine-producing microbial strains.
Dong, H; Li, F; Li, N; Liu, Y; Zhang, D; Zu, X, 2015
)
2.11
"Cytidine is a precursor of several antiviral drugs. "( Enhancement of cytidine production by coexpression of gnd, zwf, and prs genes in recombinant Escherichia coli CYT15.
Chen, N; Fang, H; Xie, X; Xu, Q; Zhang, C, 2013
)
2.19
"[3H]Cytidine is an ideal precursor for RNA."( [Problems associated with the labelling of RNA with radioactive precursors in vivo (author's transl)].
Dahnke, HG, 1975
)
0.74

Effects

ExcerptReferenceRelevance
"Cytidine has also been shown to be replaced in these RNAs by 5-fluorocytidine, a metabolic product of 5-fluorouracil, but to a considerably lesser extent."( Specific incorporation of 5-fluorocytidine into Escherichia coli RNA.
Frendewey, DA; Kaiser, II; Kladianos, DM, 1985
)
1.27

Actions

Cytidine did not inhibit the incorporation of [14C]deoxycytidine into DNA. Cytidine deaminase can cause the deamination of cytotoxic analogues of cytidine or rescue cells from the cytotoxicity of uracil analogues.

ExcerptReferenceRelevance
"Cytidine did not inhibit the incorporation of [14C]deoxycytidine into DNA while deoxycytidine decreased the incorporation of [14C]cytidine into DNA."( Studies directed toward testing the "channeling" hypothesis--ribonucleotides----DNA in leukemia L1210 cells.
Bacon, PE; Chiba, P; Cory, JG, 1984
)
0.99
"Cytidine deaminase can cause the deamination of cytotoxic analogues of cytidine or rescue cells from the cytotoxicity of uracil analogues. "( In-situ cytidine-deaminase activity and chromosome 1P deletion in human neuroblastoma cells.
Bodlaender, JM; Slingerland, RJ; Van Gennip, AH; Van Kuilenburg, AB; Voûte, PA,
)
2.01

Toxicity

ExcerptReferenceRelevance
" At concentrations of up to 50 microM no natural 2'-deoxynucleosides, including thymidine, were able to reverse the toxic effects of AZT."( Uridine reverses the toxicity of 3'-azido-3'-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity.
Carlisle, R; Schinazi, RF; Sommadossi, JP; Zhou, Z, 1988
)
0.27
" Due to CPE-C's in vivo myelotoxicity, it was important to characterize its potential adverse effects on human marrow cells during preclinical development of the drug."( In vitro characterization of the myelotoxicity of cyclopentenyl cytosine.
Du, DL; Grieshaber, CK; Murphy, MJ; Volpe, DA, 1994
)
0.29
" In conclusion, the combination of dFdC and CPEC is highly toxic to neuroblastoma in vitro."( Cyclopentenyl cytosine-induced activation of deoxycytidine kinase increases gemcitabine anabolism and cytotoxicity in neuroblastoma.
Bierau, J; Caron, HN; Leen, R; Meinsma, R; van Gennip, AH; van Kuilenburg, AB, 2006
)
0.59
" The fluorescence properties of dZeb were used to quantify the amount of this analog incorporated into cellular DNA of mismatch repair-deficient cells expressing Dm-dNK and the results showed that in a mismatch correction-defective strain a high percentage of DNA bases may be replaced with the analog without long term toxic effects."( Use of Drosophila deoxynucleoside kinase to study mechanism of toxicity and mutagenicity of deoxycytidine analogs in Escherichia coli.
Betham, B; Bhagwat, AS; Marquez, VE; Shalhout, S, 2010
)
0.58
" All 21 patients enrolled experienced at least one adverse event."( A phase I study to determine the safety and pharmacokinetics of intravenous administration of TAS-106 once per week for three consecutive weeks every 28 days in patients with solid tumors.
Abbruzzese, JL; Friday, B; Lassere, Y; Meyers, CA; Mita, A; Thomas, MB, 2012
)
0.38
" Some have hypothesized that the active metabolites of toxic ribonucleoside analogs, the triphosphate forms, inadvertently target human mitochondrial RNA polymerase (POLRMT), thus inhibiting mitochondrial RNA transcription and protein synthesis."( Structure-activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs.
Behera, I; Beigelman, L; Chaudhuri, S; Deval, J; Dyatkina, N; Jekle, A; Jin, Z; Kinkade, A; Rajwanshi, VK; Smith, DB; Symons, JA; Tucker, K; Wang, G, 2017
)
0.46
" All patients experienced a treatment emergent adverse event (TEAE) with the most common diarrhea, nausea, and fatigue."( A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma.
Babiker, H; Benaim, E; Borad, MJ; Bullock, AJ; Burhani, N; Elquza, E; Heaton, C; Hicks, LG; Mahadevan, D; Ocean, AJ; Peterson, C; Schlegel, PJ, 2022
)
0.72
" We conducted a meta-analysis to investigate the improvement in mortality or hospitalization rates and adverse events among COVID-19 patients with three new oral antivirals (including molnupiravir, fluvoxamine and Paxlovid)."( Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis.
Chen, C; Cheng, Y; Feng, Z; Mao, Q; Tang, J; Wang, C; Wang, M; Wen, W; Wu, Q; Zhang, X; Zhou, M; Zhou, X, 2022
)
0.72
" In addition, the three oral drugs did not increase the occurrence of adverse events, thus exhibiting good overall safety."( Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis.
Chen, C; Cheng, Y; Feng, Z; Mao, Q; Tang, J; Wang, C; Wang, M; Wen, W; Wu, Q; Zhang, X; Zhou, M; Zhou, X, 2022
)
0.72
"36) for any adverse events (AEs); at 200, 400 and 800 mg compared with placebo (200 mg: RR = 0."( Rapid review and meta-analysis of adverse events associated with molnupiravir in patients with COVID-19.
Amani, B; Zareei, S, 2022
)
0.72
"This meta-analysis showed that the use of three doses of molnupiravir (200, 400 and 800 mg) is safe for COVID-19 patients."( Rapid review and meta-analysis of adverse events associated with molnupiravir in patients with COVID-19.
Amani, B; Zareei, S, 2022
)
0.72
" Molnupiravir was also extremely safe since 13 (6."( Safety and efficacy of molnupiravir in SARS-CoV-2-infected patients: A real-life experience.
Babudieri, S; Bacciu, S; Bitti, A; Colpani, A; De Vito, A; Denti, L; Fois, M; Madeddu, G; Maida, I; Marcia, C; Meloni, MC; Zauli, B, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
" NBMPR-P and other inhibitors of nucleoside transport may have therapeutic applications in manipulation of the pharmacokinetic behavior and toxicity of nucleoside drugs."( Modification by nitrobenzylthioinosine-5'-monophosphate of pseudoisocytidine pharmacokinetics in mice and rats through inhibition of membrane transport.
Chou, TC; Kolassa, N; Paterson, AR, 1983
)
0.5
" The time to Cmax was found to be from 30 to 45 min for the brain and from 15 to 30 min for muscle."( Pharmacokinetics and distribution over the blood-brain barrier of zalcitabine (2',3'-dideoxycytidine) and BEA005 (2', 3'-dideoxy-3'-hydroxymethylcytidine) in rats, studied by microdialysis.
Borg, N; Ståhle, L, 1998
)
0.52
" These pharmacodynamic features of TAS-106 may explain the strong antitumor activity without serious toxicity, observed on intermittent administration schedules, in nude rat models with human tumors."( Antitumor activity and pharmacokinetics of TAS-106, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine.
Fujioka, A; Fukushima, M; Kato, T; Kazuno, H; Matsuda, A; Murakami, Y; Ohshimo, H; Sasaki, T; Shimamoto, Y, 2001
)
0.31
" However, pharmacokinetic studies revealed that 2'-C-methylcytidine suffers from a low oral bioavailability."( Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine.
Amador, A; Benzaria, S; Bridges, EG; Cretton-Scott, E; D'Amours, M; Gosselin, G; Mao, J; Mathieu, S; Moussa, A; Pierra, C; Sommadossi, JP; Standring, DN; Storer, R, 2006
)
0.79
" Plasma and urine sampling were performed during the first course to characterize the pharmacokinetic profile of TAS-106 and assess pharmacodynamic relationships."( Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.
Abbruzzese, JL; de Bono, J; Hammond-Thelin, LA; Hoff, P; Iwasaki, M; Lassere, Y; Matsushita, H; Meyers, CA; Mita, A; Norris, J; Rowinsky, EK; Thomas, MB, 2012
)
0.63
" The terminal elimination half-life (t(1/2)) averaged 11."( Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.
Abbruzzese, JL; de Bono, J; Hammond-Thelin, LA; Hoff, P; Iwasaki, M; Lassere, Y; Matsushita, H; Meyers, CA; Mita, A; Norris, J; Rowinsky, EK; Thomas, MB, 2012
)
0.63
" The present study was undertaken to evaluate the absolute oral bioavailability of FNC in rats and the pharmacokinetic properties of FNC after intragastric administration of single and multiple doses in rats and dogs."( Quantification of 2'-deoxy-2'-β-fluoro-4'-azidocytidine in rat and dog plasma using liquid chromatography-quadrupole time-of-flight and liquid chromatography-triple quadrupole mass spectrometry: Application to bioavailability and pharmacokinetic studies.
Chang, J; Chen, X; Cheng, T; Dong, L; Guo, M; Guo, X; Jiang, J; Peng, Y; Wang, Q; Zhang, J; Zhang, Y, 2014
)
0.66
" When co-delivered with pSL, zebularine increased cellular gemcitabine concentration by 4-fold, and extended the half-life of gemcitabine in plasma by 22-fold in rats."( Zebularine suppressed gemcitabine-induced senescence and improved the cellular and plasma pharmacokinetics of gemcitabine, augmented by liposomal co-delivery.
Leung, E; Lozano Hernandez, L; Reginald-Opara, JN; Svirskis, D; Tang, M; Wang, H; Wu, Z, 2021
)
0.62
"The pharmacokinetic alteration of an antimicrobial medication leading to sub-therapeutic plasma level can aid in the emergence of resistance, a global threat nowadays."( Impact of Disease States on the Oral Pharmacokinetics of EIDD-1931 (an Active Form of Molnupiravir) in Rats for Implication in the Dose Adjustment.
Ahmed, A; Bhardwaj, M; Dhiman, S; Gour, A; Khajuria, P; Manhas, D; Mukherjee, D; Nandi, U; Wazir, P, 2023
)
0.91

Compound-Compound Interactions

ExcerptReferenceRelevance
" The present study evaluated the efficacy and safety of R1626 administered for 4 weeks in combination with peginterferon alfa-2a +/- ribavirin in HCV genotype 1-infected treatment-naive patients."( R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin.
Chan, A; Everson, GT; Fried, MW; Ghalib, R; Godofsky, E; Harrison, S; Hill, G; Najera, I; Nelson, D; Nyberg, L; Pockros, PJ; Rodriguez-Torres, M; Shiffman, ML, 2008
)
0.35
" Hence, combinations of nucleoside analogues beta-D-2'-C-methylcytidine (2'-C-MeC; NM-107) or beta-D-2'-deoxy-2'-fluoro-2'-C-methyleytidine (2'-F-C-MeC; PSI-6130) with interferon-alpha2b (IFN-alpha2b) or triple combination with ribavirin (RBV) were evaluated."( Combinations of 2'-C-methylcytidine analogues with interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system.
Bassit, L; Bennett, M; Grier, J; Schinazi, RF, 2008
)
0.88
"Huh-7 cells containing the self-replicating subgenomic HCV replicon (Clone B) were used for drug combination studies."( Combinations of 2'-C-methylcytidine analogues with interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system.
Bassit, L; Bennett, M; Grier, J; Schinazi, RF, 2008
)
0.64
" The current study was designed to evaluate the effect of zebularine in comparison to and in combination with trichostatin A (TSA) on p21Cip1/Waf1/Sdi1, p27Kip1, p57Kip2, DNA methyltransferases (DNMT1, 3a and 3b) and histone deacetylases (HDAC1, 2, and 3) genes expression, cell growth inhibition and apoptosis induction in colon cancer LS 180 cell line."( Investigation of the Effect of Zebularine in Comparison to and in Combination with Trichostatin A on p21Cip1/Waf1/ Sdi1, p27Kip1, p57Kip2, DNA Methyltransferases and Histone Deacetylases in Colon Cancer LS 180 Cell Line.
Kavoosi, F; Sanaei, M, 2020
)
0.56
" The present study was designed to investigate the effect of zebularine in comparison to and in combination with trichostatin A on p21Cip1/Waf1/Sdi1, p27Kip1, p57Kip2, DNMT1, DNMT3a and DNMT3b, Class I HDACs (HDACs 1, 2, 3) and Class II HDACs (HDACs 4, 5, 6) gene expression, cell growth inhibition and apoptosis induction in colon cancer LS 174T cell line."( Effect of Zebularine in Comparison to and in Combination with Trichostatin A on CIP/KIP Family (p21Cip1/Waf1/Sdi1, p27Kip1, and p57Kip2), DNMTs (DNMT1, DNMT3a, and DNMT3b), Class I HDACs (HDACs 1, 2, 3) and Class II HDACs (HDACs 4, 5, 6) Gene Expression,
Kavoosi, F; Sanaei, M, 2020
)
0.56
" Molecular docking revealed that wild-type CES2 and its variant R180H used different sets of amino acids to interact with molnupiravir."( The COVID-19 Oral Drug Molnupiravir Is a CES2 Substrate: Potential Drug-Drug Interactions and Impact of CES2 Genetic Polymorphism In Vitro.
Eades, W; Liu, W; Shen, Y; Yan, B, 2022
)
0.72
"Studies have shown that fluorescence spectroscopy combined with BP neural network can effectively predict the concentration of ningnanmycin."( Detection of Ningnanmycin Using Fluorescence Spectroscopy Combined with BP Neural Network.
Bian, H; Feng, X; Han, Y; Ji, R; Jiang, Z; Wang, M; Wang, X; Xu, J; Yang, Y, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
"1 h in plasma and an oral bioavailability of 38%."( Pharmacology and pharmacokinetics of the antiviral agent beta-D-2',3'-dideoxy-3'-oxa-5-fluorocytidine in cells and rhesus monkeys.
Asif, G; Beltran, T; Chen, H; Chu, CK; Grier, J; Hernandez-Santiago, BI; Hurwitz, SJ; Liotta, DC; Mao, S; McClure, HM; Schinazi, RF, 2005
)
0.55
" R1626, a tri-isobutyl ester prodrug of R1479, was developed to increase bioavailability and improve antiviral activity."( Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C.
Berns, H; Cooksley, G; Dore, GJ; Hill, G; Klumpp, K; Najera, I; Roberts, SK; Robson, R; Shaw, D; Washington, C, 2008
)
0.35
" Valproate amide 3 is orally bioavailable and releases gemcitabine into the systemic circulation after passing through the intestinal mucosa."( Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine.
Bao, J; Bender, DM; Dantzig, AH; Diseroad, WD; Law, KL; Magnus, NA; McCarthy, JR; Perkins, EJ; Peterson, JA; Pu, YJ; Remick, DM; Reutzel-Edens, SM; Starling, JJ; Stephenson, GA; Vaid, RK; Zhang, D, 2009
)
0.35
"2 μM and showing moderate in vivo bioavailability in rat (F=14%)."( Discovery of 4'-azido-2'-deoxy-2'-C-methyl cytidine and prodrugs thereof: a potent inhibitor of Hepatitis C virus replication.
Agback, T; Belfrage, AK; Benckestock, K; Boothee, M; de Kock, H; Johansson, NG; Jonckers, TH; Kalayanov, G; Klumpp, K; Lachau-Durand, S; Lin, TI; Lindqvist, A; Martin, JA; Nilsson, M; Pelcman, M; Pinho, P; Raboisson, P; Rosenquist, S; Rydegård, C; Samuelsson, B; Simmen, K; Smith, DB; Sund, C; Terelius, Y; Vandyck, K; Vrang, L; Wähling, H; Wikström, K; Winqvist, A; Zhou, XX, 2012
)
0.64
" The aims of the present study were to investigate the cellular uptake of mizoribine in CNT1- and CNT2-expressing Madin-Darby canine kidney type II (MDCKII) cells, and to evaluate the effect of salt intake on bioavailability of mizoribine in healthy Japanese volunteers with SLC28A1 565-A/A and -G/A alleles."( Effect of salt intake on bioavailability of mizoribine in healthy Japanese males.
Fukao, M; Hashimoto, Y; Ishida, K; Matsukura, H; Miyawaki, T; Taguchi, M; Uemura, O; Unadkat, JD; Watanabe, H; Zhang, Z, 2013
)
0.39
" The present study was undertaken to evaluate the absolute oral bioavailability of FNC in rats and the pharmacokinetic properties of FNC after intragastric administration of single and multiple doses in rats and dogs."( Quantification of 2'-deoxy-2'-β-fluoro-4'-azidocytidine in rat and dog plasma using liquid chromatography-quadrupole time-of-flight and liquid chromatography-triple quadrupole mass spectrometry: Application to bioavailability and pharmacokinetic studies.
Chang, J; Chen, X; Cheng, T; Dong, L; Guo, M; Guo, X; Jiang, J; Peng, Y; Wang, Q; Zhang, J; Zhang, Y, 2014
)
0.66
"Zebularine is a second-generation, highly stable hydrophilic inhibitor of DNA methylation with oral bioavailability that preferentially target cancer cells."( Zebularine induces replication-dependent double-strand breaks which are preferentially repaired by homologous recombination.
Burgos-Morón, E; Calderón-Montaño, JM; Domínguez, I; Helleday, T; Huertas Castaño, C; López-Lázaro, M; Mateos, S; Orta, ML; Pastor, N, 2017
)
0.46
" Because of its tumor selective activation, novel mechanism of action, excellent oral bioavailability and candidate biomarkers for patient selection, RX-3117 has the potential to replace gemcitabine in the treatment of a spectrum of cancer types."( RX-3117 (fluorocyclopentenyl cytosine): a novel specific antimetabolite for selective cancer treatment.
Balboni, B; Benaim, E; El Hassouni, B; Giovannetti, E; Heaton, C; Honeywell, RJ; Kim, DJ; Lee, YB; Peters, GJ; Peterson, C; Poore, J; Sarkisjan, D, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" The published clinical data indicate a good safety profile, tolerability, and oral bioavailability of molnupiravir in humans."( Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19.
Al-Shammeri, AM; Alam, MT; Alaqel, SI; Alhazmi, BD; Alshammari, MK; Alshehri, MM; Alshrari, AS; Asdaq, SMB; Harshan, AA; Imran, M; Khan, SA; Kumar Arora, M; Mateq Ali, A, 2021
)
0.62
" Molnupiravir is an orally bioavailable antiviral drug for use at home when a SARS-CoV-2 test is positive."( Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients.
Parums, DV, 2022
)
0.72
" The oral bioavailability and potent antiviral activity of molnupiravir highlight its potential utility as a therapeutic candidate against COVID-19."( Molnupiravir and Its Antiviral Activity Against COVID-19.
An, X; Fan, H; Fan, J; Li, M; Lou, F; Pang, Z; Song, L; Tian, L; Tong, Y; Zhu, S, 2022
)
0.72

Dosage Studied

1-[3,5-difluorophenyl]-1,3-propandiol is an efficient prodrug modification. This inverse dose-response relationship mimics the previously reported effect of 5-methyl cytidine on mammary tumour growth in C3H mice.

ExcerptRelevanceReference
" The same dosage of tolerogen did not reverse a strongly established anti-nucleoside antibody production after a tertiary response."( Nucleoside specificity in the carrier IgG-dependent induction of tolerance.
Borel, Y; Stollar, BD, 1976
)
0.26
"The influence of cytidine dosage on uptake and distribution of [3H]cytidine by the uterus of the adult ovariectomized control rat was examined 20 min after injecting the nucleoside."( Factors affecting cytidine uptake and utilization by the rat uterus.
Greenman, DL, 1977
)
0.93
" A dose-response relationship between the amount of acetic acid and the rate of DNA synthesis was found between the dose levels of 33 to 833 mumoles of acetic acid per application."( Acetic acid, a potent stimulator of mouse epidermal macromolecular synthesis and hyperplasia but with weak tumor-promoting ability.
Boutwell, RK; Bowden, GT; Slaga, TJ, 1975
)
0.25
" The results are discussed in the light of behavioural findings in which intraperitoneally applied D-galactosamine at this dosage improves the retention performance of an acquired behaviour in the rat."( Effects of intraperitoneally applied D-galactosamine on uridine and cytidine plasma content and brain activity of uridine kinase in the rat.
Matthies, H; Popov, N; Staak, S, 1989
)
0.51
"The dose-response effects of intracerebroventricular (ICV) infusion of the pyrimidine ribonucleosides cytidine and uridine and the purine ribonucleoside adenosine on sleep and wakefulness (W) in rats were examined and compared."( A comparison of the dose response effects of pyrimidine ribonucleosides and adenosine on sleep in rats.
Crane, RA; Radulovacki, M; Rapoza, D; Virus, RM, 1985
)
0.48
" This inverse dose-response relationship mimics the previously reported effect of 5-methyl cytidine on mammary tumour growth in C3H mice."( Inhibition of urethan induced lung tumour growth in strain A mice by 5-methyl cytidine.
Theiss, JC, 1980
)
0.71
"3 kb repeat units, and could thus give rise to double dosage levels of an X-linked gene."( Long-range sequence analysis in Xq28: thirteen known and six candidate genes in 219.4 kb of high GC DNA between the RCP/GCP and G6PD loci.
Burough, F; Chen, CN; Chen, EY; Ciccodicola, A; D'Urso, M; Heiner, C; Mazzarella, R; Repetto, M; Schlessinger, D; Zollo, M; Zuo, L, 1996
)
0.29
"We examined the effects of dosage schedule on antitumor activity in vitro and in vivo to determine the optimal administration schedule for a new nucleoside antimetabolite 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106)."( Antitumor activity and pharmacokinetics of TAS-106, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine.
Fujioka, A; Fukushima, M; Kato, T; Kazuno, H; Matsuda, A; Murakami, Y; Ohshimo, H; Sasaki, T; Shimamoto, Y, 2001
)
0.31
" Addition of benzyloxycarbonyl-val-ala-asp-fluoromethylketone (Z-VAD-FMK), a broad-spectrum caspase inhibitor, attenuated the increased lethality, but the dose-response curve obtained was found to merely revert to that obtained for cells exposed to X rays alone."( X irradiation induces the proapoptotic state independent of the loss of clonogenic ability in Chinese hamster V79 cells.
Asanuma, T; Iizuka, D; Inanami, O; Kashiwakura, I; Kuwabara, M; Matsuda, A, 2005
)
0.33
" The method has been used to simultaneously determine the total concentrations of ribavirin and viramidine in monkey RBC following 5, 15, and 36 weeks dosing of viramidine or ribavirin (60 mg/kg)."( LC-MS/MS method for simultaneous determination of viramidine and ribavirin levels in monkey red blood cells.
Bu, W; Dadgostari, S; Lin, CC; Nguyen, M; Yeh, LT, 2007
)
0.34
" Low dosage of CPEC seems necessary and intensive cardiac monitoring is advisable."( Cyclopentenyl cytosine (CPEC): an overview of its in vitro and in vivo activity.
Gelderblom, H; Guchelaar, HJ; Schimmel, KJ, 2007
)
0.34
" Further research is needed to determine the appropriate patient selection and dosing schedules."( Review: recent clinical trials in epigenetic therapy.
Issa, JP; Oki, Y, 2006
)
0.33
" Dosing of R1626 was limited by neutropenia; a study of different dosages of R1626 in combination with peginterferon alfa-2a and ribavirin is underway."( R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin.
Chan, A; Everson, GT; Fried, MW; Ghalib, R; Godofsky, E; Harrison, S; Hill, G; Najera, I; Nelson, D; Nyberg, L; Pockros, PJ; Rodriguez-Torres, M; Shiffman, ML, 2008
)
0.35
" Our SAR studies ultimately led to compounds that gave high levels of NTP in hamster and rat liver after subcutaneous dosing and that were devoid of the toxic phenol moiety usually found in ProTides."( Phosphoramidate prodrugs of 2'-C-methylcytidine for therapy of hepatitis C virus infection.
Attenni, B; Di Marco, A; Donghi, M; Fiore, F; Gardelli, C; Gennari, N; Giuliano, C; Harper, S; Laufer, R; Leone, JF; MacCoss, M; Marcucci, I; Meppen, M; Narjes, F; Olsen, DB; Pacini, B; Pucci, V; Rowley, M, 2009
)
0.62
" The feasibility of such a formulation approach in humans was evaluated with the aim of developing a solid dosage form for the peroral delivery of nucleosides and showed that these excipients do provide a potential valuable tool in pre-clinical efficacy studies to drive discovery programs forward."( Enhancement of intestinal absorption of 2-methyl cytidine prodrugs.
Attenni, B; Cianetti, S; Cooper, VB; Fiore, F; Gardelli, C; Giuliano, C; Laufer, R; Monteagudo, E; Narjes, F; Pearce, GE; Pucci, V; Rowley, M, 2010
)
0.62
" However, due to a cumulative drug-related peripheral sensory neuropathy that proved to be dose-limiting, further evaluation of this bolus every 21 day infusion schedule will not be pursued and instead, an alternate dosing schedule of TAS-106 administered as a continuous 24-hour infusion will be explored to decrease C(max) in efforts to minimize peripheral neuropathy and maximize antitumor activity."( Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.
Abbruzzese, JL; de Bono, J; Hammond-Thelin, LA; Hoff, P; Iwasaki, M; Lassere, Y; Matsushita, H; Meyers, CA; Mita, A; Norris, J; Rowinsky, EK; Thomas, MB, 2012
)
0.63
" The oral dosing of 23 led to substantially increased exposure to 5 in both rats and dogs."( 2'-Deoxy-2'-spirocyclopropylcytidine revisited: a new and selective inhibitor of the hepatitis C virus NS5B polymerase.
Berke, JM; Buyck, C; Cummings, MD; de Kock, H; Dillen, LL; Fanning, G; Hu, L; Jonckers, TH; Lachau-Durand, S; Lin, TI; Nilsson, M; Raboisson, P; Rosenquist, A; Rydegård, C; Samuelsson, B; Simmen, K; Sund, C; Van Emelen, K; Van Hoof, S; Vandekerckhove, LA; Vandyck, K; Vijgen, L, 2010
)
0.65
" Screening for 2'-C-methylcytidine triphosphate levels in rat liver after oral dosing identified 1-[3,5-difluorophenyl]-1,3-propandiol as an efficient prodrug modification."( Antiviral efficacy upon administration of a HepDirect prodrug of 2'-C-methylcytidine to hepatitis C virus-infected chimpanzees.
Boyer, SH; Carroll, SS; Erion, MD; Fujitaki, JM; Handt, L; Hecker, SJ; Koeplinger, K; Linemeyer, DL; MacCoss, M; Olsen, DB; Reddy, KR; Sun, Z; van Poelje, PD; Vavrek, M; Zhang, NR, 2011
)
0.9
"Differential progression of global DNA hypomethylation was studied by comparatively dosing zebularine (ZEB) and 5-azacytidine (AZA)."( 3-D DNA methylation phenotypes correlate with cytotoxicity levels in prostate and liver cancer cell models.
Gertych, A; Oh, JH; Tajbakhsh, J; Wawrowsky, KA; Weisenberger, DJ, 2013
)
0.6
" This review summarizes the current data for the most commonly used drugs for coronavirus disease 2019 and will cover the unique factors that may affect the dosing of these medications in patients with CKD."( Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function.
Govil, A; Luckett, K; Miller-Handley, H, 2020
)
0.56
" Single and multiple ascending dose (SAD and MAD, respectively) cohorts were dosed in randomized, double-blind, and placebo-controlled fashion, with a 6:2 active-to-placebo ratio in each cohort."( Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2.
Bush, J; Cohen, O; Holman, W; McIntosh, S; Painter, G; Painter, W, 2021
)
0.62
" The patient-compliant oral dosage form of molnupiravir may hit the market in the first or second quarter of 2022."( Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19.
Al-Shammeri, AM; Alam, MT; Alaqel, SI; Alhazmi, BD; Alshammari, MK; Alshehri, MM; Alshrari, AS; Asdaq, SMB; Harshan, AA; Imran, M; Khan, SA; Kumar Arora, M; Mateq Ali, A, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
cytidines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (28)

PathwayProteinsCompounds
Pyrimidine Metabolism2353
beta-Ureidopropionase Deficiency2353
UMP Synthase Deficiency (Orotic Aciduria)2353
Dihydropyrimidinase Deficiency2353
MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy)2353
Pyrimidine Ribonucleosides Degradation511
Operon: Nucleotide and Deoxyribonucleotide Catabolism Inactivation IV11
UTP and CTP dephosphorylation I113
pyrimidine ribonucleosides salvage I29
superpathway of pyrimidine ribonucleosides salvage720
pyrimidine ribonucleosides salvage II27
Pyrimidine Nucleotides and Nucleosides metabolism ( Pyrimidine Nucleotides and Nucleosides metabolism )4549
Biomarkers for pyrimidine metabolism disorders1432
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-20490
Pyrimidine synthesis and deprivation pathway (COVID-19 Disease Maps)1329
15q25 copy number variation08
pyrimidine ribonucleosides degradation513
nucleoside and nucleotide degradation (archaea)722
pyrimidine ribonucleosides salvage III613
superpathway of pyrimidine ribonucleosides salvage2237
pyrimidine ribonucleosides salvage I613
pyrimidine ribonucleosides salvage II812
superpathway of pyrimidine ribonucleosides degradation1317
UTP and CTP dephosphorylation I314
salvage pathways of pyrimidine ribonucleotides936
pyrimidine ribonucleosides degradation II28
superpathway of ribose and deoxyribose phosphate degradation024
(deoxy)ribose phosphate degradation018
purine and pyrimidine metabolism032
salvage pathways of purine and pyrimidine nucleotides030
pyrimidine ribonucleosides degradation I07
Biochemical pathways: part I0466
Pyrimidine metabolism038
Pyrimidine metabolism and related diseases1844

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.35480.003245.467312,589.2998AID2517
EWS/FLI fusion proteinHomo sapiens (human)Potency0.03860.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
chromobox protein homolog 1Homo sapiens (human)Potency56.23410.006026.168889.1251AID540317
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.81070.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glucose transporterLeishmania mexicanaIC50 (µMol)12.00000.08102.30676.7450AID1207598
Hexose transporter 1 Plasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)12.00000.09002.22205.8850AID1207597
Solute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)IC50 (µMol)12.00000.00492.99549.9920AID1207599
Calcium-dependent protein kinase 1Plasmodium falciparum 3D7IC50 (µMol)1.00000.00210.00760.0130AID1159502
Lysine--tRNA ligase Plasmodium falciparum 3D7IC50 (µMol)2.50000.12000.12000.1200AID1159505
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Deoxycytidine kinaseHomo sapiens (human)Km6.60000.40003.57908.5000AID278932
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (33)

Processvia Protein(s)Taxonomy
central nervous system developmentSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
response to hypoxiaSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
female pregnancySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
long-chain fatty acid import across plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
L-ascorbic acid metabolic processSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cerebral cortex developmentSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cellular response to glucose starvationSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
xenobiotic transportSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
photoreceptor cell maintenanceSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
protein-containing complex assemblySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cellular response to mechanical stimulusSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cellular hyperosmotic responseSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose import across plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
response to Thyroglobulin triiodothyronineSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose transmembrane transportSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose importSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
response to insulinSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
dehydroascorbic acid transportSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
pyrimidine nucleotide metabolic processDeoxycytidine kinaseHomo sapiens (human)
CMP biosynthetic processDeoxycytidine kinaseHomo sapiens (human)
dAMP salvageDeoxycytidine kinaseHomo sapiens (human)
nucleoside phosphate biosynthetic processDeoxycytidine kinaseHomo sapiens (human)
cell surface receptor signaling pathwayCytidine deaminaseHomo sapiens (human)
pyrimidine-containing compound salvageCytidine deaminaseHomo sapiens (human)
cytidine deaminationCytidine deaminaseHomo sapiens (human)
cytosine metabolic processCytidine deaminaseHomo sapiens (human)
negative regulation of cell growthCytidine deaminaseHomo sapiens (human)
UMP salvageCytidine deaminaseHomo sapiens (human)
negative regulation of nucleotide metabolic processCytidine deaminaseHomo sapiens (human)
response to cycloheximideCytidine deaminaseHomo sapiens (human)
cellular response to external biotic stimulusCytidine deaminaseHomo sapiens (human)
CMP biosynthetic processUridine-cytidine kinase 1 Homo sapiens (human)
UMP salvageUridine-cytidine kinase 1 Homo sapiens (human)
CTP salvageUridine-cytidine kinase 1 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
long-chain fatty acid transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
protein bindingSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
kinase bindingSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
dehydroascorbic acid transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
identical protein bindingSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
D-glucose transmembrane transporter activitySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
deoxyadenosine kinase activityDeoxycytidine kinaseHomo sapiens (human)
deoxycytidine kinase activityDeoxycytidine kinaseHomo sapiens (human)
deoxyguanosine kinase activityDeoxycytidine kinaseHomo sapiens (human)
ATP bindingDeoxycytidine kinaseHomo sapiens (human)
protein homodimerization activityDeoxycytidine kinaseHomo sapiens (human)
cytidine kinase activityDeoxycytidine kinaseHomo sapiens (human)
nucleoside bindingCytidine deaminaseHomo sapiens (human)
cytidine deaminase activityCytidine deaminaseHomo sapiens (human)
protein bindingCytidine deaminaseHomo sapiens (human)
zinc ion bindingCytidine deaminaseHomo sapiens (human)
identical protein bindingCytidine deaminaseHomo sapiens (human)
protein homodimerization activityCytidine deaminaseHomo sapiens (human)
uridine kinase activityUridine-cytidine kinase 1 Homo sapiens (human)
ATP bindingUridine-cytidine kinase 1 Homo sapiens (human)
cytidine kinase activityUridine-cytidine kinase 1 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (28)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
Golgi membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
female germ cell nucleusSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
photoreceptor inner segmentSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
female pronucleusSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cytosolSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
caveolaSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
intercalated discSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
basolateral plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
Z discSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
midbodySolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
cortical actin cytoskeletonSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
sarcolemmaSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
melanosomeSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
extracellular exosomeSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
blood microparticleSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
presynapseSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
glucose transporter complexSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
basolateral plasma membraneSolute carrier family 2, facilitated glucose transporter member 1Homo sapiens (human)
nucleoplasmDeoxycytidine kinaseHomo sapiens (human)
cytosolDeoxycytidine kinaseHomo sapiens (human)
mitochondrionDeoxycytidine kinaseHomo sapiens (human)
cytoplasmDeoxycytidine kinaseHomo sapiens (human)
extracellular regionCytidine deaminaseHomo sapiens (human)
cytosolCytidine deaminaseHomo sapiens (human)
secretory granule lumenCytidine deaminaseHomo sapiens (human)
tertiary granule lumenCytidine deaminaseHomo sapiens (human)
ficolin-1-rich granule lumenCytidine deaminaseHomo sapiens (human)
cytosolCytidine deaminaseHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
cytosolUridine-cytidine kinase 1 Homo sapiens (human)
cytoplasmUridine-cytidine kinase 1 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (95)

Assay IDTitleYearJournalArticle
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID278936Activity of human UCK1 expressed in Huh7 cells assessed as phosphorylation by coupled enzyme assay2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Mechanism of activation of beta-D-2'-deoxy-2'-fluoro-2'-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase.
AID1879226Antiviral activity against HCV by replicon assay2022Bioorganic & medicinal chemistry letters, 04-01, Volume: 61Design, chemical synthesis and antiviral evaluation of 2'-deoxy-2'-fluoro-2'-C-methyl-4'-thionucleosides.
AID102531Inhibitory effect tested in vitro for the growth of Lung adenocarcinoma PC-8 cell line1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Nucleosides and nucleotides. 100. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosyl-cytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID205931Inhibitory effect tested in vitro for the growth of Stomach adenocarcinoma ST-KM cell line1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Nucleosides and nucleotides. 100. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosyl-cytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside.
AID102530Inhibitory effect tested in vitro for the growth of Lung adenocarcinoma PC-3 cell line1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Nucleosides and nucleotides. 100. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosyl-cytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside.
AID55385Inhibition of cytidine deaminase partially purified from mouse kidney.1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
2'-O-nitro-1-beta-D-arabinofuranosylcytosine. A new derivative of 1-beta-D-arabinofuranosylcytosine that resists enzymatic deamination and has antileukemic activity.
AID151162Inhibitory effect tested in vitro for the growth of Osteosarcoma KHOS-321H cell line1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Nucleosides and nucleotides. 100. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosyl-cytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside.
AID431226Activity of cloned cytidine deaminase in human HuH7 cells by spectrophotometric analysis2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
The mechanism of action of beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine involves a second metabolic pathway leading to beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine 5'-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.
AID431228Ratio of Kcat to Km for cloned cytidine deaminase in human HuH7 cells by spectrophotometric analysis2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
The mechanism of action of beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine involves a second metabolic pathway leading to beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine 5'-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.
AID205930Inhibitory effect tested in vitro for the growth of Stomach adenocarcinoma NUGC-4 cell line1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Nucleosides and nucleotides. 100. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosyl-cytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside.
AID278932Activity of human dCK expressed in HepG2 cells assessed as phosphorylation by coupled enzyme assay2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Mechanism of activation of beta-D-2'-deoxy-2'-fluoro-2'-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID205927Inhibitory effect tested in vitro for the growth of Stomach adenocarcinoma MKN- 28 cell line1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Nucleosides and nucleotides. 100. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosyl-cytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside.
AID210890Ability to inhibit rat cytoplasmic Thymidine kinase1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Species- or isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes.
AID28713Partition coefficient (logP)1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Chemistry and anti-HIV properties of 2'-fluoro-2',3'-dideoxyarabinofuranosylpyrimidines.
AID97847The concentration requiredi (cytidine+2'deoxycytidine) to inhibit the growth of L-1210 leukemic cells was evaluated1985Journal of medicinal chemistry, Apr, Volume: 28, Issue:4
Synthesis and biological activity of a novel adenosine analogue, 3-beta-D-ribofuranosylthieno[2,3-d]pyrimidin-4-one.
AID377832Antioxidant activity assessed as 3-morpholinosydnonimine-derived peroxynitrite free radical scavenging activity after 30 mins2005Journal of natural products, Apr, Volume: 68, Issue:4
Chemical constituents of the fruits of Morinda citrifolia (Noni) and their antioxidant activity.
AID151163Inhibitory effect tested in vitro for the growth of Osteosarcoma MNNG-HOS cell line1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Nucleosides and nucleotides. 100. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosyl-cytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside.
AID126601Ability to inhibit rat mitochondrial thymidine kinase1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Species- or isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes.
AID201571Phosphorylation by uridine/cytidine kinase(UCK) from mouse sarcoma -180 ascites cells was measured.1998Journal of medicinal chemistry, Jul-16, Volume: 41, Issue:15
Nucleosides and nucleotides. 175. Structural requirements of the sugar moiety for the antitumor activities of new nucleoside antimetabolites, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine and -uracil1.
AID102684Inhibitory effect tested in vitro for the growth of Lung squamous-cell carcinoma QG-56 cell line1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Nucleosides and nucleotides. 100. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosyl-cytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside.
AID151164Inhibitory effect tested in vitro for the growth of Osteosarcoma OST cell line1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Nucleosides and nucleotides. 100. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosyl-cytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside.
AID102529Inhibitory effect tested in vitro for the growth of Lung adenocarcinoma PC-13 cell line1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Nucleosides and nucleotides. 100. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosyl-cytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside.
AID717236Binding affinity to Streptomyces avidinii streptavidin at 4 mM using dye labeled Streptavidin binding aptamer by fluorescence spectral analysis method2012Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23
Specific interactions between adenosine and streptavidin/avidin.
AID102532Inhibitory effect tested in vitro for the growth of Lung adenocarcinoma PC-9 cell line1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Nucleosides and nucleotides. 100. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosyl-cytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside.
AID151165Inhibitory effect tested in vitro for the growth of Osteosarcoma SK-ES-1 cell line1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Nucleosides and nucleotides. 100. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosyl-cytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside.
AID377831Antioxidant activity assessed as authentic peroxynitrite free radical scavenging activity after 30 mins2005Journal of natural products, Apr, Volume: 68, Issue:4
Chemical constituents of the fruits of Morinda citrifolia (Noni) and their antioxidant activity.
AID278933Ratio of Kcat to Km for human dCK expressed in HepG2 cells2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Mechanism of activation of beta-D-2'-deoxy-2'-fluoro-2'-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase.
AID278937Ratio of Kcat to Km for UCK1 activity expressed in Huh7 cells2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Mechanism of activation of beta-D-2'-deoxy-2'-fluoro-2'-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase.
AID97844The concentration required to inhibit the growth of L-1210 leukemic cells was evaluated; 1E-3 to 1E-41985Journal of medicinal chemistry, Apr, Volume: 28, Issue:4
Synthesis and biological activity of a novel adenosine analogue, 3-beta-D-ribofuranosylthieno[2,3-d]pyrimidin-4-one.
AID377830Antioxidant activity assessed as DPPH radical scavenging activity after 30 mins2005Journal of natural products, Apr, Volume: 68, Issue:4
Chemical constituents of the fruits of Morinda citrifolia (Noni) and their antioxidant activity.
AID219877Inhibitory effect tested in vitro for the growth of colon adenocarcinoma SW-480 cell line1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Nucleosides and nucleotides. 100. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosyl-cytosine (CNDAC): design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside.
AID18296Michaelis-Menten constant was determined against cytidine deaminase1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
Cyclic urea nucleosides. Cytidine deaminase activity as a function of aglycon ring size.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,814)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901142 (40.58)18.7374
1990's320 (11.37)18.2507
2000's497 (17.66)29.6817
2010's520 (18.48)24.3611
2020's335 (11.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 64.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index64.75 (24.57)
Research Supply Index7.99 (2.92)
Research Growth Index4.64 (4.65)
Search Engine Demand Index114.76 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (64.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials35 (1.20%)5.53%
Reviews131 (4.49%)6.00%
Case Studies7 (0.24%)4.05%
Observational1 (0.03%)0.25%
Other2,744 (94.04%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]